Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients
| Autor: | Hendrik J. Agteresch, Sjaak A Burgers, Ate van der Gaast, Pieter C. Dagnelie, J. H. Paul Wilson |
|---|---|
| Přispěvatelé: | Internal Medicine, Pulmonary Medicine, Medical Oncology, Radiology & Nuclear Medicine, Epidemiologie, RS: NUTRIM School of Nutrition and Translational Research in Metabolism |
| Rok vydání: | 2003 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Cachexia Lung Neoplasms Antineoplastic Agents Gastroenterology law.invention Adenosine Triphosphate Randomized controlled trial Quality of life SDG 3 - Good Health and Well-being law Internal medicine Carcinoma Non-Small-Cell Lung Weight Loss medicine Carcinoma Humans Pharmacology (medical) Lung cancer Aged Pharmacology business.industry Proportional hazards model Middle Aged medicine.disease Confidence interval Surgery Clinical trial Oncology Female business |
| Zdroj: | Anti-Cancer Drugs, 14, 639-644. Lippincott Williams & Wilkins Anti-Cancer Drugs, 14(8), 639-644. LIPPINCOTT WILLIAMS & WILKINS |
| ISSN: | 0959-4973 |
| Popis: | Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC.Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.We recently reported that regular infusions of adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life in patients with non-small cell lung cancer (NSCLC). In the present paper we investigated whether ATP affects tumor growth and survival in the same group of patients. Fifty-eight NSCLC patients (stage IIIB or IV) were randomly assigned to receive either 10 i.v. 30-h ATP infusions every 2-4 weeks over a 24-week period (n = 28) or no ATP (control patients, n = 30). ATP was given for a median of 6.5 infusions. Differences in time to progression and survival between patients in both groups were tested by means of the log-rank test and Cox regression analysis. Forty-nine patients were evaluable for tumor response. None of the evaluable patients showed a complete or partial response. Median time to progression was 3.9 months [95% confidence interval (CI) = 2.3-5.5] in the ATP group compared to 3.0 months (95% CI = 2.4-3.7) in the control group (p = 0.71). Median survival was 5.6 months (95% CI = 1.1-10.1) for the ATP group and 4.7 months (95% CI = 2.6-6.8) for the control group (p = 0.68). ATP treatment was associated with a significant increase in survival in the subgroup of weight-losing patients with stage IIIB NSCLC: in this subgroup, median survival was 9.3 months (95% CI = 2.1-16.5) for ATP-treated patients versus 3.5 months (95% CI = 2.3-4.7) for control patients (between-group difference: p = 0.009). No significant effect of ATP was observed for weight-losing patients with stage IV NSCLC or for weight-stable NSCLC patients. Although ATP as a single therapy does not lead to tumor regression or increased survival in patients with advanced lung cancer, it may prolong survival in weight-losing patients with stage IIIB lung cancer. The latter finding is intriguing, but requires confirmation in larger clinical trials |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|